Keywords
How to Cite
Abstract
Introduction: Ozempic (Semaglutide) is a medication used to treat type 2 diabetes. However, it has been used indiscriminately for weight loss purposes, mainly by young women. Although it is a proven effective option, its use without medical supervision has harmful consequences for the health of its users, due to its adverse effects. Methodology: This is an integrative literature review. The bibliographic research was carried out in the electronic databases BVS, SCIELO and PubMed, in addition to information obtained from official government websites, such as the WHO, Ministry of Health and ANVISA. The search used descriptors such as: “Ozempic AND Weight loss” and “Semaglutide AND Weight loss”, and adopted inclusion and exclusion criteria. Results and Discussion: Studies show that Ozempic promotes significant weight loss, ranging from 6% to 20% of body weight in periods of 3 to 68 weeks. Additional benefits include improvements in glucose levels and blood pressure. Adverse effects such as nausea, vomiting, and diarrhea have been reported, being more frequent in off-label use. Semaglutide demonstrates efficacy in weight control and in reducing cardiovascular risks. Patients without diabetes present better results in weight loss. Despite this, its indiscriminate use raises ethical and safety concerns, reinforcing the need for medical supervision. Conclusion: Ozempic represents an effective tool in the management of obesity, but it should be used with professional supervision to mitigate adverse effects and avoid inappropriate practices. Future studies are needed to optimize its use and explore therapeutic combinations.
References
ALABDULJABBAR. K. et al. Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting. Endocrine, 21 set. 2023.
ABESO - Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. Diretrizes brasileiras de obesidade 2016 – 4.ed. - São Paulo, SP, 2016.
BASER, O. et al. The association between weight loss medications and cardiovascular complications. Obesity, 6 maio 2024.
GHUSN, W. et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open, v. 5, n. 9, p. e2231982, 19 set. 2022.
GOMES. H. K. B. C.; TREVISAN. M. O uso do ozempic (semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Revista Artigos. Com, v. 29, p. e7498, 29 jun. 2021.
MOIZ, A. et al. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American Journal of Cardiology, v. 222, p. 121–130, 26 abr. 2024.
Organização Mundial da Saúde (1998). Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. Geneva. Disponível em: file:///C:/Users/EXTRA/Downloads/WHO_TRS_894.pdf. Acesso em: 03. Jan. 2025
Organização Mundial da Saúde (2024). Uma em cada oito pessoas, no mundo, vive com obesidade - OPAS/OMS. Disponível em: <https://www.paho.org/pt/noticias/1-3-2024-uma-em-cada-oito-pessoas-no-mundo-vive-com-obesidade>. Acesso em: 03. Jan. 2025.
POWELL, W. C. et al. Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world data. Obesity, v. 31, n. 10, p. 2482–2492, 18 ago. 2023.
RODRIGUES, K. et al. EFEITOS DO USO DO OZEMPIC (SEMAGLUTIDA) NO TRATAMENTO DA OBESIDADE. Revista Multidisciplinar do Nordeste Mineiro, v. 13, n. 1, 29 nov. 2023.
RUBINO, D. et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, v. 325, n. 14, p. 1414–1425, 13 abr. 2021.
SABBÁ, H. B. O. et al. Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis. Research, Society and Development, v. 11, n. 11, p. e587111133963, 4 set. 2022.
TRABULSI, R. K. et al. As consequências clínicas do uso de Ozempic para tratamento da obesidade: uma revisão de literatura. Brazilian Journal of Health Review, v. 6, n. 3, p. 12297–12312, 12 jun. 2023.
WANDERLEY, E. N.; FERREIRA, V. A. Obesidade: uma perspectiva plural. Ciência & Saúde Coletiva, v. 15, n. 1, p. 185–194, 1 jan. 2010.
WILDING, J. P. H.; BATTERHAM, R. L.; CALANNA, S. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, v. 384, n. 11, p. 989–1002, 10 fev. 2021.
ZIMMERER, E. N. et al. EFFECTS OF USING OZEMPIC (SEMAGLUTIDE) IN THE TREATMENT OF OBESITY. RevistaMultidisciplinar doNordesteMineiro,v.13,2023ISSN 2178-6925.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Ana Luisa Albuquerque Miranda, Isabella Ferreira Silva, Clara Carvalho e Lanna, Ana Luísa Esteves de Barcellos Emery Pereira, Isabella Vitória Barbosa Silva, Catarina Paiva Verona Lima, Guilherme Fiorino Bissoli, Larissa Marta Sacramento de Freitas, Nagile Gariff Garcia Guimarães, Melina Barroso Amaro de Castro, Karine Barbosa Castro, Franciny Baêta Lacerda, Maria Clara de Paula Silva